MadeMed's Oral Tirzepatide, Reviewed: Pricing, Format, and What to Expect
Key Takeaways
- MadeMed offers compounded oral tirzepatide in tablet form — one of the few providers with this format
- Pricing: $119/month (monthly) or $89/month (quarterly plan, billed every 3 months)
- This is a compounded medication — not the FDA-approved Mounjaro/Zepbound (which are injectable only)
- No FDA-approved oral tirzepatide exists yet — Lilly's oral version is still in clinical trials
- MadeMed also offers oral semaglutide at the same price points
MadeMed is one of the few telehealth providers offering compounded oral tirzepatide — a format that doesn't exist as an FDA-approved product. Here's what that means, how the pricing works, and what to consider before starting.
What MadeMed Offers
| Product | Format | Monthly Plan | Quarterly Plan |
|---|---|---|---|
| Oral semaglutide | Compounded tablet | $119/mo | $89/mo |
| Oral tirzepatide | Compounded tablet | $119/mo | $89/mo |
The quarterly plan bills every 3 months ($267 per quarter) and locks in the $89/month rate. The monthly plan is $119 with no commitment — cancel anytime.
MadeMed also offers an optional $149/year "MadeMed Club" membership, which is separate from the medication subscription.
How It Works
- Online consultation: Complete a health questionnaire and asynchronous provider review
- Prescription: If approved, a licensed provider writes a prescription for compounded oral tirzepatide
- Compounding pharmacy: A licensed 503A compounding pharmacy prepares the medication
- Shipping: Direct-to-door delivery
The Compounded Context
MadeMed's oral tirzepatide is compounded by a licensed pharmacy — it is not the FDA-approved Mounjaro (diabetes) or Zepbound (weight loss), both of which are injectable only. There is no FDA-approved oral tirzepatide on the market. Eli Lilly is developing one, but it's still in clinical trials.
Compounded medications use the same active ingredient but are not FDA-reviewed for safety, efficacy, or manufacturing consistency. They are legal when prescribed by a licensed provider and prepared by a properly licensed compounding pharmacy.
Why Oral Tirzepatide Matters
Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two metabolic pathways rather than one (like semaglutide, which targets GLP-1 only). In injectable form, tirzepatide has shown higher weight-loss percentages than semaglutide in head-to-head trials.
MadeMed's oral format gives needle-averse patients access to tirzepatide without injection — something that won't be available as an FDA-approved product until Lilly completes its oral tirzepatide development program (estimated 2027+).
How It Compares
| Provider | Oral Tirzepatide | Price | Notes |
|---|---|---|---|
| MadeMed | Compounded tablet | $89–$119/mo | Sema also available at same price |
| Telos Rx | Compounded oral | $40 first mo, then $160–249 | Lower entry, higher maintenance |
| Zepbound (injectable) | N/A — injection only | $299–$449/mo | FDA-approved, different format |
MadeMed
Oral TirzepatideCompounded oral tirzepatide tablets. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
Telos Rx
Oral TirzepatideCompounded oral tirzepatide via Telos Rx. First-month pricing starts at $40; ongoing pricing varies by plan length ($160–249/mo).
MadeMed's oral tirzepatide is one of the most affordable ways to access tirzepatide without injections. The quarterly plan at $89/month undercuts most compounded injectable tirzepatide pricing. The trade-off: it's a compounded product without FDA-approved oral tirzepatide data to benchmark against. If you want oral tirzepatide at the lowest available price point, MadeMed is a top option; if you need FDA-approved products, you'll wait for Lilly's pipeline or use injectable Zepbound.
Prices verified as of July 2026. This is a compounded medication, not FDA-approved. Review carried out independently. Consult your healthcare provider about appropriateness.